secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-08-13T20:02:40+00:00
Accession:  0001178913-26-004122
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion closes $2.5M public offering; converts $750K debt to equity
--------------------------------------------------------------------

- Offered 2,028,619 shares, 1,817,542 pre-funded warrants, 3,846,161 Series E warrants at $0.65/unit; gross proceeds ~$2.5M.
- Net proceeds ~$2.1M; intended for SIL204 clinical trial and general corporate purposes.
- Converted $750,001 of sponsor note into 1,153,848 ordinary shares at $0.65/share; note balance now $206,462.
- Issued 823,770 shares from pre-funded warrant exercises; adjusted shareholders' equity ~$3.2M as of June 30, 2026.
- H.C. Wainwright sole placement agent; fees 7% cash, 1% management, plus 269,231 placement agent warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004122/0001178913-26-004122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004122/zk2635949.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-004122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer